Three drugs differently jam TB’s RNA-making enzyme

Mycobacterium tuberculosis depends on its RNA polymerase (RNAP) to copy genetic information during transcription elongation, a step that can be interrupted at pause sequences. To learn how small molecules interfere with that process, a team led by Carlos Bustamante compared three different inhibitors and watched how the enzyme behaved when they were present. The study focused on transcription elongation by MtbRNAP and probed how each compound changed the enzyme’s progress through the DNA. Rather than treating all inhibitors as doing the same thing, the researchers set out to reveal whether each drug altered the mechanical motions of RNAP or its tendency to pause and backtrack. By reporting how D-IX216, Stl, and PUM affect the enzyme, the work maps distinct outcomes — from slowed movement to induced pausing and altered nucleotide incorporation — that help explain why these small molecules have different impacts on the same molecular machine. The effort highlights detailed behavioral differences in RNAP that are invisible in simpler assays but are central to how transcription is stopped or slowed.

The results show strikingly different effects for the three small-molecule inhibitors on transcription elongation by MtbRNAP. D-IX216 inhibits RNAP active-center bridge-helix motions required for nucleotide addition; in its presence the enzyme switches between slowly and super-slowly elongating inhibited states. Stl, which inhibits the RNAP trigger-loop motions also required for nucleotide addition, inhibits RNAP primarily by inducing pausing and backtracking. PUM, a nucleoside analog of UTP, in addition to acting as a competitive inhibitor, induces the formation of slowly elongating RNAP inhibited states. Together these observations indicate three classes of small-molecule inhibitors affect the enzyme in distinct ways. The study also reports that the combination of Stl and D-IX216, which both target the RNAP bridge helix, has a strong synergistic effect on the enzyme, amplifying inhibition beyond what either compound does alone. These specific outcomes — altered bridge-helix or trigger-loop motions, pausing, backtracking, and competitive blocking — define clear mechanistic differences among the compounds.

Understanding these pleomorphic effects matters because it shows that chemically distinct inhibitors can stall the same enzyme by different mechanical routes. The finding that D-IX216 produces slowly and super-slowly elongating inhibited states, while Stl drives pausing and backtracking, and PUM combines competitive inhibition with slowed states, gives a richer picture of how transcription can be interrupted. That richness includes the possibility of combining drugs to take advantage of synergy: the reported strong synergistic effect of Stl and D-IX216 suggests that pairing inhibitors that influence overlapping motions of RNAP could produce greater blockade than single agents. At the molecular level, revealing multiple inhibited states and distinct failure modes of MtbRNAP points to new strategies for disrupting transcription elongation. By cataloguing how each molecule reshapes RNAP dynamics, the work provides a mechanistic foundation that can guide further studies into how best to target the enzyme’s motions and vulnerabilities.